Company: ARWR
Filing Date: 2025-01-29
Form Type: DEF 14A
Source: 0001628280-25-002848
Chunk: 8

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: DEF 14A
Chunk 8
---
 Senior Vice President and CFO of Ilypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. Before joining Ilypsa, he served as the founder and principal at Square One Finance, a financial consulting business. Mr. Waddill received a BS in accounting from the University of Illinois, Chicago, and certification as a public accountant (inactive) after working at PriceWaterhouseCoopers and Deloitte in Boston. |
| Qualifications                                                                                                                                                                                                                       
 Mr. Waddill’s qualifications to serve on the Board include his extensive background in the biopharma industry, his financial and audit expertise, executive leadership roles and experience as a director of other public companies. |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

| 11 |

2025 PROXY STATEMENT Proposal One — Election of Directors Board Composition and Nominating Process

The Nomination Committee of the Board annually considers the size, composition and needs of the Board and, as appropriate, recommends the nominees for directors to the Board for approval. The Nomination Committee considers and evaluates suggestions from many sources regarding possible candidates for directors. Below are general criteria for the evaluation of current and proposed directors: • The highest ethical character and shared values with our Code of Corporate Conduct • Reputation, both personal and professional, consistent with our image and reputation • Accomplishment within a candidate’s field, with superior credentials and recognition • Relevant expertise and experience and the ability to offer advice and guidance to the Chief Executive Officer based on such expertise and experience • Independence, without the appearance of any conflict in serving as a Director, and independence of any particular constituency with the ability to represent all stockholders • Ability to exercise sound business judgment • Diversity, reflecting differences in skills, regional and industry experience, backgrounds, ages, and other unique characteristics, such as race, gender and ethnicity The Nomination Committee considers the mix of skills and experience among current and prospective directors with a goal of assembling a Board with complementary skills for the benefit of the Company. Listed below are selected key contributions of each current Board member. The table is not intended to be an exhaustive summary of all the contributions of each Board member.

| Expertise            |     | Given |     | Perry |     | Anzalone |     | Ferrari |     | Olukotun |     | Vakiener |     | Waddill |     | Lu |     | Ingram |
| Biopharma Research   
 & Development        |     | X     |     | X     |